title: Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
abstract: Tropomyosin receptor kinases (TrkA/B/C) play crucial roles in the development and maintenance of the nervous system, and aberrant expression of Trk has been implicated in neurological disorders as well as neural and non-neural neoplasms. Patent activity encompassing Trk inhibitors has grown substantially over the last 6 years, recognized by a rise in the number of pharmaceutical entrants to the field and the escalation of novel inhibitor chemotypes. Area covered: In Part I of this two part review, a biological and structural overview of Trk is provided in the context of Trk as a therapeutic target for cancer and pain, followed by the report of recent patent literature claiming small molecule inhibitors of Trk family kinases or which describe inhibitors developed for other kinase targets but include noteworthy Trk inhibition/application. The discussion of the patent literature continues in Part II of this review, which includes an in-depth view of the current clinical applications of Trk inhibitors. Expert opinion: Substantial synthetic efforts in Trk inhibitor development has propagated numerous and diverse inhibitor chemotypes, including TrkA-specific inhibitors. While many novel Trk inhibitors remain the original progeny of Trk-specific development programs, kinase inhibitors initially developed for other kinases have also been successfully repositioned for Trk.
authors.affiliation: a Faculty of Medicine & Dentistry , University of Alberta, Department of Oncology , Edmonton , AB , Canada.
authors.forename: Justin J
authors.initials: JJ
authors.lastname: Bailey
authors.affiliation: a Faculty of Medicine & Dentistry , University of Alberta, Department of Oncology , Edmonton , AB , Canada.
authors.forename: Ralf
authors.initials: R
authors.lastname: Schirrmacher
authors.affiliation: a Faculty of Medicine & Dentistry , University of Alberta, Department of Oncology , Edmonton , AB , Canada.
authors.forename: Kristen
authors.initials: K
authors.lastname: Farrell
authors.affiliation: a Faculty of Medicine & Dentistry , University of Alberta, Department of Oncology , Edmonton , AB , Canada.
authors.forename: Vadim
authors.initials: V
authors.lastname: Bernard-Gauthier
mesh_terms: D000818:Animals; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology; D010330:Patents as Topic; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D020917:Receptor, trkA / Q000037:antagonists & inhibitors*; D020813:Receptor, trkB / Q000037:antagonists & inhibitors*; D020812:Receptor, trkC / Q000037:antagonists & inhibitors*
chemical_list: D047428:Protein Kinase Inhibitors; D020917:Receptor, trkA; D020813:Receptor, trkB; D020812:Receptor, trkC
keywords: LOXO-101; NTRK1/2/3; TrkA; TrkB; TrkC; Tropomyosin receptor kinase; cancer treatment; chronic pain; entrectinib; oncology; pruritis; targeted therapy; tropomyosin receptor kinase inhibitor